Formulation and evaluation of Cyclosporin A emulgel for ocular delivery

Drug Delivery

Volumn 22, Issue 7, 2015, Pages 911-917

  Shen, Yan ^a   Ling, Xiang ^a   Jiang, Weiwei ^b   Du, Shuang ^a   Lu, Yang ^c   Tu, Jiasheng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Patent Examination Cooperation Center of SIPO   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cyclosporin A; emulgel; ocular delivery; polycarbophil; precorneal clearance

Indexed keywords

CYCLOSPORIN A; POLYCARBOPHIL; ACRYLIC ACID RESIN; CYCLOSPORIN; DRUG CARRIER; EMULSION; EXCIPIENT; GEL; IMMUNOSUPPRESSIVE AGENT; POLYCARBOPHIL CALCIUM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; AREA UNDER THE MOMENT CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG STORAGE; EMULSION; FLOW KINETICS; GEL; INTRAOCULAR DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PROCEDURES; RABBIT;

ACRYLIC RESINS; ADMINISTRATION, OPHTHALMIC; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; DRUG STABILITY; DRUG STORAGE; EMULSIONS; EXCIPIENTS; GELS; IMMUNOSUPPRESSIVE AGENTS; RABBITS; RHEOLOGY;

EID: 84942870719     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.861883     Document Type: Article

References (29)

1. Balasubramaniam J, Kant S, Pandit JK. (2003). In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin. Acta Pharm 53:251-61.
2. Belin MW, Bouchard CS, Phillips TM. (1990). Update on topical cyclosporin A. Background, immunology, and pharmacology. Cornea 9:184-95.
3. Benitez del Castillo JM, del Aguila C, Duran S, et al. (1994). Influence of topically applied cyclosporine A in olive oil on corneal epithelium permeability. Cornea 13:136-40.
4. Bother H, Waaler T. (1990). Rheological characterization of tear substitutes. Drug Dev Ind Pharm 16:755-68.
5. Chen Y, Lu Y, Zhong Y, et al. (2012). Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation. J Drug Target 20:856-63.
6. Costa P. (2001). An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm 220:77-83.
7. Diebold Y, Jarrin M, Saez V, et al. (2007). Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 28:1553-64.
8. Du S, Sun CM, Shen Y, et al. (2011). Study on ophthalmic emulsion-gel of Cyclosporine A. Pharm Clin Res 19:215-19.
9. Er Y, Barnes TJ, Fornasiero D, et al. (2009). The encapsulation and release of guanosine from PEGylated liposomes. J Liposome Res 19: 29-36.
10. Gupta V, Bansal P, Gupta A, et al. (2010). Formulation and evaluation of topical gel of diclofenac sodium using different polymers. Drug Invention Today 2:250-3.
11. Kishore AS, Surekha P, Murthy PB. (2009). Assessment of the dermal and ocular irritation potential of multi-walled carbon nanotubes by using in vitro and in vivo methods. Toxicol Lett 191:268-74.
12. Krenzer KL, Zhang JZ, Coffey MJ, et al. (2012). Safety of repeated topical ocular administration of a polycarbophil-based formulation in several models of ocular surgery in rabbits. J Cataract Refract Surg 38: 696-704.
13. Kumar L, Verma R. (2011). In vitro evaluation of topical gel prepared using natural polymer. Int J Drug Deliv 2:58-63.
14. Lallemand F, Felt-Baeyens O, Besseghir K, et al. (2003). Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 56:307-18.
15. Marquardt D, Sucker H. (1998). Oil-in water-emulsion gels: determination and mathematical treatment of flow properties. Eur J Pharm Biopharm 46:115-24.
16. Mohamed MI. (2004). Optimization of chlorphenesin emulgel formulation. AAPS Journal 6:e26-32.
17. Mondon K, Zeisser-Labouèbe M, Gurny R, et al. (2011). Novel Cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study. Eur J Pharm Biopharm 77:56-65.
18. Niazi SK. (2009). Stability testing of new drug substances and products. In: Niazi SK, ed. Handbook of pharmaceutical manufacturing formulations. (second ed.). New York: Informa Healthcare, 52-9.
19. Parrott EL. (1970). Pharmaceutical technology: fundamental pharmaceutics. Lincoln, USA: Burgess Publishing Company.
20. Perioli L, Pagano C, Mazzitelli S, et al. (2008). Rheological and functional characterization of new antiinflammatory delivery systems designed for buccal administration. Int J Pharm 356:19-28.
21. Rodriguez-Aller M, Kaufmann B, Guillarme D, et al. (2012). In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. Eur J Pharm Biopharm 80:544-52.
22. Schreiber SL, Crabtree GR. (1992). The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136-42.
23. Schumacher A, Nordheim A. (1992). Progress towards a molecular understanding of cyclosporin A-mediated immunosuppression. Clin Investig 70:773-9.
24. Shahin M, Hady SA, Hammad M, et al. (2011). Novel jojoba oil-based emulsion gel formulations for clotrimazole delivery. APS PharmSciTech 12:239-47.
25. Steiger M. (2010). Topical emulsion-gel composition comprising diclofenac sodium. US Patent 7,732,489 B2.
26. Stevenson D, Tauber J, Reis BL. (2000). Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107:967-74.
27. Van Haeringen NJ. (1981). Clinical biochemistry of tears. Surv Ophthalmol 26:84-96.
28. Van Ooteghem MMM. (1993). Formulation of ophthalmic solutions and suspensions. Problems and advantages. In: Edman P, ed. Biopharmaceutics of ocular drug delivery. Boca Raton, FL: CRC Press, 27-42.
29. Wei G, Xu H, Ding PT, et al. (2002). Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release 83:65-74.